Predictors of progression in Barrett's esophagus: current knowledge and future directions
- PMID: 20104216
- PMCID: PMC3408387
- DOI: 10.1038/ajg.2010.2
Predictors of progression in Barrett's esophagus: current knowledge and future directions
Abstract
Barrett's esophagus (BE) is the strongest risk factor for esophageal adenocarcinoma (EAC), a malignancy with persistently poor long-term outcomes. EAC is thought to develop through progression of metaplasia to dysplasia to invasive carcinoma. Identification of factors predicting progression to EAC would help in focusing surveillance, chemoprevention, or ablation for those deemed to be at highest risk of progression. We performed a comprehensive review of the literature and summarized current evidence on risk factors for progression in subjects with known BE. Clinical and demographic factors (age, male gender, length of BE segment) are associated with modestly increased odds of progression to EAC in some studies. Biomarkers such as aneuploidy and p53 loss of heterozygosity have been associated with increased risk of progression to high-grade dysplasia and/or EAC in single-center prospective cohort studies. Promising newer techniques and markers have been recently reported with the potential to help risk stratify BE subjects. Development of a comprehensive BE risk progression score comprised of both clinical and biomarker variables should be the ultimate goal and can be achieved by multicenter prospective collaborative efforts. Although it would be challenging, creation of such a score has the potential to improve outcomes and make the management of patients with BE more cost-effective.
Figures

Similar articles
-
Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.Am J Gastroenterol. 2001 Oct;96(10):2839-48. doi: 10.1111/j.1572-0241.2001.04236.x. Am J Gastroenterol. 2001. PMID: 11693316 Free PMC article.
-
Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.Am J Gastroenterol. 2009 Nov;104(11):2673-80. doi: 10.1038/ajg.2009.437. Epub 2009 Jul 28. Am J Gastroenterol. 2009. PMID: 19638963
-
Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.Gastroenterol Clin North Am. 2015 Jun;44(2):299-315. doi: 10.1016/j.gtc.2015.02.005. Epub 2015 Mar 31. Gastroenterol Clin North Am. 2015. PMID: 26021196 Free PMC article. Review.
-
Biomarkers in Barrett's esophagus.Gastrointest Endosc Clin N Am. 2003 Apr;13(2):369-97. doi: 10.1016/s1052-5157(03)00006-0. Gastrointest Endosc Clin N Am. 2003. PMID: 12916666 Review.
-
Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.United European Gastroenterol J. 2021 Oct;9(8):929-937. doi: 10.1002/ueg2.12114. Epub 2021 Jul 6. United European Gastroenterol J. 2021. PMID: 34228885 Free PMC article.
Cited by
-
A Molecular Clock Infers Heterogeneous Tissue Age Among Patients with Barrett's Esophagus.PLoS Comput Biol. 2016 May 11;12(5):e1004919. doi: 10.1371/journal.pcbi.1004919. eCollection 2016 May. PLoS Comput Biol. 2016. PMID: 27168458 Free PMC article.
-
Differences in the Characteristics of Barrett's Esophagus and Barrett's Adenocarcinoma between the United States and Japan.ISRN Gastroenterol. 2013 Mar 28;2013:840690. doi: 10.1155/2013/840690. Print 2013. ISRN Gastroenterol. 2013. PMID: 23606979 Free PMC article.
-
Gastroesophageal reflux disease and tooth erosion.Int J Dent. 2012;2012:479850. doi: 10.1155/2012/479850. Epub 2011 Dec 12. Int J Dent. 2012. PMID: 22194748 Free PMC article.
-
Barrett's oesophagus: epidemiology, cancer risk and implications for management.Gut. 2014 Jan;63(1):191-202. doi: 10.1136/gutjnl-2013-305490. Epub 2013 Oct 3. Gut. 2014. PMID: 24092861 Free PMC article. Review.
-
Surveillance for low-grade dysplastic Barrett's oesophagus: one size fits all?World J Surg. 2015 Mar;39(3):578-85. doi: 10.1007/s00268-014-2661-5. World J Surg. 2015. PMID: 24919861 Review.
References
-
- Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–6. - PubMed
-
- Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease:a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–20. quiz 1943. - PubMed
-
- Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus:international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005;62:488–98. - PubMed
-
- Corley DA, Levin TR, Habel LA, et al. Surveillance and survival in Barrett’s adenocarcinomas:a population-based study. Gastroenterology. 2002;122:633–40. - PubMed
-
- Ferguson MK, Durkin A. Long-term survival after esophagectomy for Barrett’s adenocarcinoma in endoscopically surveyed and nonsurveyed patients. J Gastrointest Surg. 2002;6:29–35. discussion 36. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous